Cytek Bio (CTKB): רווח נקי למניה (EPS TTM)

Cytek Biosciences, Inc. (CTKB) is recognized as an impeccable technological authority in cellular diagnostics. The rolling earnings per share trend confirms this status, where the -0.63 metric determines the status of the yield parameter. The company generates revenue through the sale of spectral cytometers and associated reagents. Income is based on the creation of innovative analysis systems for medical laboratories and pharmaceutical development.

This indicator reflects the trailing twelve-month net income divided by the total number of shares, allowing for an assessment of the actual return on each share of ownership. The trend in the 12-month per-share net income of Cytek Biosciences, Inc. (CTKB) demonstrates capital sensitivity to specialized medical logistics and equipment calibration costs, directly impacting the final asset management efficiency of Cytek Biosciences, Inc. (CTKB).